# Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer

> **NCT00305942** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 61 (actual)

## Conditions studied

- Carcinoma, Small Cell

## Interventions

- **DRUG:** Topotecan
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT00305942
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2009-04
- **Final completion:** 2009-11
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2013-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305942, "Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00305942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*